Investigation of FE 999302 and Follitropin Delta in Controlled Ovarian Stimulation for Infertility in Women Undergoing Assisted Reproductive Technologies

The primary objective of this exploratory study is to investigate the effect of **FE 999302** when administered in conjunction with **follitropin delta** during controlled ovarian stimulation in women experiencing **infertility** and undergoing assisted reproductive technologies (ART). This study is clinically relevant as it aims to enhance the understanding of potential therapeutic strategies to improve ovarian response and outcomes in ART, which is a critical aspect of infertility treatment.

The clinical trial focuses on **infertility in women undergoing assisted reproductive technologies (ART)**. The study population consists exclusively of female participants, as male subjects are not included. The age range of the participants is categorized under code "3," which typically corresponds to adults, although specific age details are not provided. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria, including lifestyle considerations such as diet, physical activity, or habits, are not specified in the available data. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed to explore the effects of **FE 999302** in combination with follitropin delta during controlled ovarian stimulation in women experiencing **infertility** and undergoing assisted reproductive technologies (ART). This study is a Phase 3 trial, which is categorized as exploratory in nature. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on July 31, 2024, to the anticipated end date on October 20, 2026.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful inclusion, participants will attend multiple follow-up visits scheduled at specific intervals to monitor the effects of the treatment and ensure participant safety. The sequence of these visits is structured to collect comprehensive data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

The expected length of participant involvement in the study is approximately two years, contingent upon the individual's response to the treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure the safety and well-being of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and methodologies employed in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 31, 2024, with an estimated completion date of October 20, 2026. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis throughout the study period. The focus will be on evaluating the treatment's impact on the specified medical condition, with results contributing to the understanding of the treatment's effectiveness in a controlled clinical setting.